Voriconazole in clinical practice

References

• Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al.. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068–75.
   PubMed Web of Science ®Google Scholar
• Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, et al.. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica. 2006;91(7):986–9.
   PubMed Web of Science ®Google Scholar
• Michallet M, Benet T, Sobh M, Kraghel S, El Hamri M, Cannas G, et al.. Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis. 2012;31(6):991–7.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, et al.. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2010;95(4):644–50.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al.. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100.
   PubMed Web of Science ®Google Scholar
• Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, et al.. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265–73.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Nosari A, Van Lint MT, Candoni A, Offidani M, et al.. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study–Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis. 2007;45(9):1161–70.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47(8):1041–50.
   PubMed Web of Science ®Google Scholar
• Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol. 2009;88(2):121–32.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Gangneux JP, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y, et al.. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect. 2011;17(12):1882–9.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal Infections Complicating Tumor Necrosis Factor alpha Blockade Therapy. Mayo Clin Proc. 2008;83(2):181–94.
   PubMed Web of Science ®Google Scholar
• Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, et al.. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003;102(8):2768–76.
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, et al.. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106(6):2018–25.
   PubMed Web of Science ®Google Scholar
• Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer. 2002;94(7):2033–9.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Aversa F, Cook P, Jones B, Michallet M, Shea T, et al.. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. Eur J Haematol. 2011;87(4):289–301.
   PubMed Web of Science ®Google Scholar
• Muhlemann K, Wenger C, Zenhausern R, Tauber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia. 2005;19(4):545–50.
   PubMed Web of Science ®Google Scholar
• Martino R, Subira M, Rovira M, Solano C, Vazquez L, Sanz GF, et al.. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol. 2002;116(2):475–82.
   PubMed Web of Science ®Google Scholar
• Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34(2):115–21.
   PubMed Web of Science ®Google Scholar
• Bjorklund A, Aschan J, Labopin M, Remberger M, Ringden O, Winiarski J, et al.. Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;40(11):1055–62.
   PubMed Web of Science ®Google Scholar
• Hebart H, Bollinger C, Fisch P, Sarfati J, Meisner C, Baur M, et al.. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood. 2002;100(13):4521–8.
   PubMed Web of Science ®Google Scholar
• Carvalho A, Cunha C, Pasqualotto AC, Pitzurra L, Denning DW, Romani L. Genetic variability of innate immunity impacts human susceptibility to fungal diseases. Int J Infect Dis. 2010;14(6):e460–8.
   PubMed Web of Science ®Google Scholar
• Mezger M, Einsele H, Loeffler J. Genetic susceptibility to infections with Aspergillus fumigatus. Crit Rev Microbiol. 2010;36(2):168–77.
   PubMed Web of Science ®Google Scholar
• Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M, et al.. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med. 2008;359(17):1766–77.
   PubMed Web of Science ®Google Scholar
• Garantziotis S, Hollingsworth JW, Zaas AK, Schwartz DA. The effect of Toll-like receptors and Toll-like receptor genetics in human disease. Annu Rev Med. 2008;59:343–59.
   PubMed Web of Science ®Google Scholar
• Carvalho A, Cunha C, Carotti A, Aloisi T, Guarrera O, Di Ianni M, et al.. Polymorphisms in Toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplantation. Exp Hematol. 2009;37(9):1022–9.
   PubMed Web of Science ®Google Scholar
• Cunha C, Di Ianni M, Bozza S, Giovannini G, Zagarella S, Zelante T, et al.. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood. 2010;116(24):5394–402.
   PubMed Web of Science ®Google Scholar
• Kumpf O, Schumann RR. Genetic variation in innate immunity pathways and their potential contribution to the SIRS/CARS debate: evidence from human studies and animal models. J Innate Immun. 2010;2(5):381–94.
   PubMed Web of Science ®Google Scholar
• Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger U, Frere P, et al.. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant. 2011;46(5):709–18.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al.. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–60.
   PubMed Web of Science ®Google Scholar
• Michallet M, Ito JI. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol. 2009;27(20):3398–409.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Fluckiger U, Gachot B, Ribaud P, Thiebaut A, Cordonnier C. Antifungal Therapy in Leukemia Patients 2009 Update of ECIL 1 and ECIL 2 Guidelines [cited 2009 Dec 30]. Available from: http://www.ichs.org/Resources/Documents/ECIL%203%20Antifungal%20therapy%20Update%202009.pdf
   Google Scholar
• Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al.. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–35.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al.. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56–93.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Hope W, Sinko J, Kibbler C. Optimizing management of invasive mould diseases. J Antimicrob Chemother. 2011;66 Suppl 1: i45–53.
   PubMed Web of Science ®Google Scholar
• Goldberg E, Gafter-Gvili A, Robenshtok E, Leibovici L, Paul M. Empirical antifungal therapy for patients with neutropenia and persistent fever: systematic review and meta-analysis. Eur J Cancer. 2008;44(15):2192–203.
   PubMed Web of Science ®Google Scholar
• Aguilar-Guisado M, Martin-Pena A, Espigado I, Ruiz Perez de Pipaon M, Falantes J, de la Cruz F, et al.. Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach. Haematologica. 2012;97(3):464–71.
   PubMed Web of Science ®Google Scholar
• Ferrara JJ, MacDougall C, Gallagher JC. Empiric antifungal therapy in patients with febrile neutropenia. Pharmacotherapy. 2011;31(4):369–85.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S, Vekhoff A, Fasrhat H, Suarez F, et al.. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48(8):1042–51.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Micozzi A, Gentile G, Santilli S, Arleo E, Cardarelli L, et al.. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol. 2010;28(4):667–74.
   PubMed Web of Science ®Google Scholar
• Maertens J, Groll AH, Cordonnier C, de la Camara R, Roilides E, Marchetti O. Treatment and timing in invasive mould disease. J Antimicrob Chemother. 2011;66 Suppl 1: i37–43.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al.. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15.
   PubMed Web of Science ®Google Scholar
• Egger SS, Meier S, Leu C, Christen S, Gratwohl A, Krahenbuhl S, et al.. Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplant. 2010;45(7):1197–203.
   PubMed Web of Science ®Google Scholar
• Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350(9):950–2.
   PubMed Web of Science ®Google Scholar
• Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, et al.. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007;40(5):451–6.
   PubMed Web of Science ®Google Scholar
• Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, et al.. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39(7):425–9.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Viscoli C. Current role of echinocandins in the management of invasive aspergillosis. Curr Infect Dis Rep. 2011;13(6):517–27.
   PubMedGoogle Scholar
• Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118(5):1216–24.
   PubMed Web of Science ®Google Scholar
• Aperis G, Alivanis P. Posaconazole: a new antifungal weapon. Rev Recent Clin Trials. 2011;6(3):204–19.
   PubMedGoogle Scholar
• Wirk B, Wingard JR. Combination antifungal therapy: from bench to bedside. Curr Infect Dis Rep. 2008;10(6):466–72.
   PubMedGoogle Scholar
• Johnson MD, Perfect JR. Use of Antifungal Combination Therapy: Agents, Order, and Timing. Curr Fungal Infect Rep. 2010;4(2):87–95.
   PubMedGoogle Scholar
• Mihu CN, Kassis C, Ramos ER, Jiang Y, Hachem RY, Raad, II. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? Cancer. 2010;116(22):5290–6.
   PubMed Web of Science ®Google Scholar
• Luke DR, Wood ND, Tomaszewski KE, Damle B. Pharmacokinetics of sulfobutylether-beta-cyclodextrin (SBECD) in subjects on hemodialysis. Nephrol Dial Transplant. 2012;27(3):1207–12.
   PubMed Web of Science ®Google Scholar
• Hafner V, Czock D, Burhenne J, Riedel KD, Bommer J, Mikus G, et al.. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother. 2010;54(6):2596–602.
   PubMed Web of Science ®Google Scholar
• Oude Lashof AM, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, et al.. Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia. Antimicrob Agents Chemother. 2012;56(6):3133–7.
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis. 2008;47(2):226–35.
   PubMed Web of Science ®Google Scholar
• Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther. 2009;7(8):981–98.
   PubMed Web of Science ®Google Scholar
• EUCAST Technical Note on voriconazole. Clin Microbiol Infect. 2008;14(10):985–7.
   PubMed Web of Science ®Google Scholar
• CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA; 2008.
   Google Scholar
• Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, Pfaller MA, Rinaldi M, Rodriguez-Tudela JL, et al.. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol. 2005;43(8):3884–9.
   PubMed Web of Science ®Google Scholar
• Chryssanthou E, Cuenca-Estrella M. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol. 2002;40(10):3841–4.
   PubMed Web of Science ®Google Scholar
• Lass-Florl C. In vitro susceptibility testing in Aspergillus species: an update. Future Microbiol. 2010;5(5):789–99.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat. 2009;12(6):141–7.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, Alexander BD, et al.. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis. 2011;70(3):330–43.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis. 2011;69(1):45–50.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Diekema DJ, Fothergill A, Johnson E, Pelaez T, Pfaller MA, et al.. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol. 2010;48(9):3251–7.
   PubMed Web of Science ®Google Scholar
• Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol. 2006;44(5):1740–3.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J Invasive Fungal Infect. 2007;1(3):74–92.
   Google Scholar
• Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005;49(2):668–79.
   PubMed Web of Science ®Google Scholar
• Borst A, Raimer MT, Warnock DW, Morrison CJ, Arthington-Skaggs BA. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob Agents Chemother. 2005;49(2):783–7.
   PubMed Web of Science ®Google Scholar
• Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002;2(2):73–85.
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Perfect JR, Schell WA, Walsh TJ, Benjamin DK. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother. 2004;48(9):3217–25.
   PubMed Web of Science ®Google Scholar
• Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother. 2010;54(11):4758–64.
   PubMed Web of Science ®Google Scholar
• Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, et al.. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5(11):e219.
   PubMedGoogle Scholar
• Tashiro M, Izumikawa K, Hirano K, Ide S, Mihara T, Hosogaya N, et al.. Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus. Antimicrob Agents Chemother. 2012;56(9):4870–5.
   PubMed Web of Science ®Google Scholar
• Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis. 2000;30(4):653–7.
   PubMed Web of Science ®Google Scholar
• Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect. 2004;10 Suppl 1: 1–10.
   PubMed Web of Science ®Google Scholar
• Lat A, Thompson GR. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist. 2011;4:43–53.
   PubMedGoogle Scholar
• Williams D. The effect of enteral nutrition supplements on serum voriconazole levels. J Oncol Pharm Pract. 2012;18(1):128–31.
   PubMedGoogle Scholar
• Pai MP, Lodise TP. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother. 2011;55(6):2601–5.
   PubMed Web of Science ®Google Scholar
• Myrianthefs P, Markantonis SL, Evaggelopoulou P, Despotelis S, Evodia E, Panidis D, et al.. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study. Int J Antimicrob Agents. 2010;35(5):468–72.
   PubMed Web of Science ®Google Scholar
• Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, et al.. Challenging Recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis. 2012;55(3):381–90.
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Curr Opin Infect Dis. 2005;18(6):484–9.
   PubMed Web of Science ®Google Scholar
• Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009;53(3):935–44.
   PubMed Web of Science ®Google Scholar
• Michael C, Bierbach U, Frenzel K, Lange T, Basara N, Niederwieser D, et al.. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother. 2010;54(8):3225–32.
   PubMed Web of Science ®Google Scholar
• Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK, Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos. 2010;38(1):25–31.
   PubMed Web of Science ®Google Scholar
• Maples HD, Stowe CD, Saccente SL, Jacobs RF. Voriconazole serum concentrations in an infant treated for Trichosporon beigelii infection. Pediatr Infect Dis. J 2003;22(11):1022–4.
   Google Scholar
• Vfend (voriconazole). EMA summary of product characteristics. Sandwich: Pfizer Limited; 2012.
   Google Scholar
• Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol. 2008;92(7):871–8.
   PubMed Web of Science ®Google Scholar
• Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003;37(5):728–32.
   PubMed Web of Science ®Google Scholar
• Clifton IJ, Whitaker P, Metcalfe R, Phillip M, Shaw N, Conway SP, et al.. Pharmacokinetics of oral voriconazole in patients with cystic fibrosis. J Antimicrob Chemother. 2011;66(10):2438–40.
   PubMed Web of Science ®Google Scholar
• Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53(1):24–34.
   PubMed Web of Science ®Google Scholar
• Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, et al.. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68(6):906–15.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim BH, Nam WS, Yoon SH, Cho JY, Shin SG, et al.. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol. Epub ahead of print 2011 Mar 7.
   Google Scholar
• Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. Voriconazole pharmacokinetics and therapeutic drug monitoring: a multi-center study. Antimicrob Agents Chemother. 2012;56(9):4793–9.
   PubMed Web of Science ®Google Scholar
• Lewis RE. Pharmacodynamic implications for use of antifungal agents. Curr Opin Pharmacol. 2007;7(5):491–7.
   PubMed Web of Science ®Google Scholar
• Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am. 2006;20(3):679–97.
   PubMed Web of Science ®Google Scholar
• Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother. 2008;61(1):17–25.
   PubMed Web of Science ®Google Scholar
• Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother. 2011;55(10):4782–8.
   PubMed Web of Science ®Google Scholar
• Vfend (voriconazole) [package insert]. New York, NY: Pfizer; 2011.
   Google Scholar
• Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, et al.. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005;35(5):509–13.
   PubMed Web of Science ®Google Scholar
• Trifilio SM, Yarnold PR, Scheetz MH, Pi J, Pennick G, Mehta J. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother. 2009;53(5):1793–6.
   PubMed Web of Science ®Google Scholar
• Shima H, Miharu M, Osumi T, Takahashi T, Shimada H. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer. 2010;54(7):1050–2.
   PubMed Web of Science ®Google Scholar
• Santos RP, Sanchez PJ, Mejias A, Benjamin DK, Walsh TJ, Patel S, et al.. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J. 2007;26(4):364–6.
   PubMed Web of Science ®Google Scholar
• Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis. 2002;35(10):1273–5.
   PubMed Web of Science ®Google Scholar
• Cecil JA, Wenzel RP. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections. Expert Rev Hematol. 2009;2(3):237–54.
   PubMed Web of Science ®Google Scholar
• Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, et al.. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33(9):1447–54.
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al.. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005;366(9495):1435–42.
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, et al.. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36(9):1122–31.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL, et al.. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54(10):4446–50.
   PubMed Web of Science ®Google Scholar
• Marr KA, Schlamm HT, Rottinghaus ST, Jagannatha S, Bow EJ, Wingard JR, et al.. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. Proceedings of the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 2012 Mar 31–Apr 3; London, UK.
   Google Scholar
• Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al.. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346(4):225–34.
   PubMed Web of Science ®Google Scholar
• Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al.. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–8.
   PubMed Web of Science ®Google Scholar
• Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, et al.. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155(3):318–27.
   PubMed Web of Science ®Google Scholar
• Mandhaniya S, Swaroop C, Thulkar S, Vishnubhatla S, Kabra SK, Xess I, et al.. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study. J Pediatr Hematol Oncol. 2011;33(8):e333–41.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K, et al.. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95(10):1762–8.
   PubMed Web of Science ®Google Scholar
• Groll AH, Kolve H, Ehlert K, Paulussen M, Vormoor J. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. J Antimicrob Chemother. 2004;53(1):113–4.
   PubMed Web of Science ®Google Scholar
• Saari TI, Laine K, Bertilsson L, Neuvonen PJ, Olkkola KT. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol. 2007;63(10):941–9.
   PubMed Web of Science ®Google Scholar
• Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther. 2006;79(4):362–70.
   PubMed Web of Science ®Google Scholar
• Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, et al.. Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol. 2009;65(3):263–71.
   PubMed Web of Science ®Google Scholar
• Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, et al.. Interaction of oxycodone and voriconazole-a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects. Eur J Clin Pharmacol. 2011;67(8):863–4.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Homma M, Momo K, Okoshi Y, Wada T, Hara A, et al.. Effects of voriconazole co-administration on oxycodone-induced adverse events: a case in the retrospective survey. Eur J Clin Pharmacol. 2011;67(8):859–61.
   PubMed Web of Science ®Google Scholar
• Saari TI, Laine K, Neuvonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol. 2008;64(1):25–30.
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–11.
   PubMed Web of Science ®Google Scholar
• Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, et al.. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50(4):1570–2.
   PubMed Web of Science ®Google Scholar
• Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, et al.. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109(8):1532–5.
   PubMed Web of Science ®Google Scholar
• Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50(1):27–36.
   PubMed Web of Science ®Google Scholar
• Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect. 2010;16(7):927–33.
   PubMed Web of Science ®Google Scholar
• Kim SH, Yim DS, Choi SM, Kwon JC, Han S, Lee DG, et al.. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Int J Infect Dis. 2011;15(11):e753–8.
   PubMed Web of Science ®Google Scholar
• Bruggemann RJ, van der Linden JW, Verweij PE, Burger DM, Warris A. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J. 2011;30(6):533–4.
   PubMed Web of Science ®Google Scholar
• Wang JL, Chang CH, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother. 2010;54(6):2409–19.
   PubMed Web of Science ®Google Scholar
• Amigues I, Cohen N, Chung D, Seo SK, Plescia C, Jakubowski A, et al.. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16(1):46–52.
   PubMed Web of Science ®Google Scholar
• Brunel AS, Fraisse T, Lechiche C, Pinzani V, Mauboussin JM, Sotto A. Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy. Aids. 2008;22(7):905–6.
   PubMed Web of Science ®Google Scholar
• Vanacker A, Fabre G, Van Dorpe J, Peetermans WE, Maes B. Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient. Am J Transplant. 2008;8(4):877–80.
   PubMed Web of Science ®Google Scholar
• Epaulard O, Saint-Raymond C, Villier C, Charles J, Roch N, Beani JC, et al.. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients. Clin Microbiol Infect. 2010;16(9):1362–4.
   PubMed Web of Science ®Google Scholar
• Patel AR, Turner ML, Baird K, Gea-Banacloche J, Mitchell S, Pavletic SZ, et al.. Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2009;15(3):370–6.
   PubMed Web of Science ®Google Scholar
• Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol. 2010;146(3):300–4.
   PubMedGoogle Scholar
• Cowen EW, Nguyen JC, Miller DD, McShane D, Arron ST, Prose NS, et al.. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol. 2010;62(1):31–7.
   PubMed Web of Science ®Google Scholar
• Vadnerkar A, Nguyen MH, Mitsani D, Crespo M, Pilewski J, Toyoda Y, et al.. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant. 2010;29(11):1240–4.
   PubMed Web of Science ®Google Scholar
• Cheng MP, Paquette K, Lands LC, Ovetchkine P, Theoret Y, Quach C. Voriconazole inhibition of vitamin A metabolism: are adverse events increased in cystic fibrosis patients? Pediatr Pulmonol. 2010;45(7):661–6.
   PubMed Web of Science ®Google Scholar
• Baxter CG, Marshall A, Roberts M, Felton TW, Denning DW. Peripheral neuropathy in patients on long-term triazole antifungal therapy. J Antimicrob Chemother. 2011;66(9):2136–9.
   PubMed Web of Science ®Google Scholar
• Aksoy F, Akdogan E, Aydin K, Yilmaz M, Altunayoglu V, Sozen EE, et al.. Voriconazole-induced neuropathy. Chemotherapy. 2008;54(3):224–7.
   PubMed Web of Science ®Google Scholar
• Porter CC, Carver AE, Albano EA. Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X. Pediatr Blood Cancer. 2009;52(2):298–300.
   PubMed Web of Science ®Google Scholar
• Wang TF, Wang T, Altman R, Eshaghian P, Lynch JP, Ross DJ, et al.. Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant. 2009;9(12):2845–50.
   PubMed Web of Science ®Google Scholar
• Ayub A, Kenney CV, McKiernan FE. Multifocal nodular periostitis associated with prolonged voriconazole therapy in a lung transplant recipient. J Clin Rheumatol. 2011;17(2):73–5.
   PubMed Web of Science ®Google Scholar
• Chen L, Mulligan ME. Medication-induced periostitis in lung transplant patients: periostitis deformans revisited. Skeletal Radiol. 2010;40(2):143–8.
   PubMed Web of Science ®Google Scholar
• Wermers RA, Cooper K, Razonable RR, Deziel PJ, Whitford GM, Kremers WK, et al.. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis. 2011;52(5):604–11.
   PubMed Web of Science ®Google Scholar